Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.)

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 11, 2009, Pages 1529-1536

  Kumar, Santosh ^a   Enjamoori, Rajesh ^a   Jaiswal, Amardeep ^a   Ray, Ruma ^a   Seth, Sandeep ^a   Maulik, Subir Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Collagen; Echocardiography; Isoprenaline; Left ventricular hypertrophy; Terminalia arjuna

Indexed keywords

ANTIFIBROTIC AGENT; CAPTOPRIL; CARDIAC AGENT; CATALASE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; GLUTATHIONE; ISOPRENALINE; SUPEROXIDE DISMUTASE; TERMINALIA ARJUNA EXTRACT; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BARK; BETA ADRENERGIC STIMULATION; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; TREATMENT DURATION;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANTIOXIDANTS; CAPTOPRIL; CARDIOMEGALY; FIBROSIS; HEART; ISOPROTERENOL; MALE; MYOCARDIUM; ORGAN SIZE; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; PHYTOTHERAPY; PLANT BARK; PLANT EXTRACTS; PLANT STEMS; RATS; RATS, WISTAR; TERMINALIA;

EID: 75749088041     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.11.0013     Document Type: Article

References (49)

1. Castellano M, Bohm M. The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 1997; 29: 715-722.
2. Lamba S, Abraham WT. Alterations in adrenergic receptor signaling in heart failure. Heart Fail Rev 2000; 5: 7-16.
3. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49: 241-248.
4. Dhalla AK et al. Role of oxidative stress in transition of hypertrophy to heart failure. J AmColl Cardiol 1996; 28: 506-514.
5. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
6. Srivastava S et al. Downregulation of Cu/Zn-superoxide dismutase contributes to beta-adrenergic receptor-mediated oxidative stress in the heart. Cardiovasc Res 2007; 74: 445-455.
7. Takemoto M et al. Statins as antioxidant therapy for preventing cardiacmyocyte hypertrophy.J ClinInvest 2001; 108: 1429-1437.
8. Shree Gulabkuverba Ayurvedic Society, ed. Charak Samhita. India. Shree Gulabkuverba Ayurvedic Society, 1949; Sutra-98: 2306.
9. Shastri VD, Bhawa Mishra, eds. Bhawaprakashnighantu. Varanasi, India: Motilal Benarasi Das, 1966: 344.
10. Manna P et al. Phytomedicinal activity of Terminalia arjuna against carbon tetrachloride induced cardiac oxidative stress. Pathophysiology 2007; 14: 71-78.
11. Gauthaman K et al. Effect of chronic treatment with bark of Terminalia arjuna: a study on the isolated ischemic-reperfused rat heart. J Ethnopharmacol 2001; 75: 197-201.
12. Gauthaman K et al. Terminalia arjuna (Roxb.) protects rabbit heart against ischemic-reperfusion injury: role of antioxidant enzymes and heat shock protein. J Ethnopharmacol 2005; 96: 403-409.
13. Sumitra M et al. Experimental myocardial necrosis in rats: role of arjunolic acid on platelet aggregation, coagulation and antioxidant status. Mol Cell Biochem 2001; 224: 135-142.
14. Singh G et al. Protective effects of Terminalia arjuna against doxorubicin-induced cardiotoxicity. J Ethnopharmacol 2008; 117: 123-129.
15. Bharani A et al. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. Int J Cardiol 1995; 49: 191-199.
16. Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Ind Heart J 1997; 49: 507-510.
17. Gupta R et al. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomized placebo-controlled trial. J Assoc Phys India 2001; 49: 231-235.
18. Stahl E. Thin layer chromatography. Berlin: Springer-Verlag, 1969.
19. Lang RM et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
20. Litwin SE et al. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994; 89: 345-354.
21. Ohkawa H et al. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Ann Biochem 1979; 95: 351-358.
22. Ellman GL. Tissue sulphydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
23. Aebi H. Catalase. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. Frankfurt: Chemic Academic Press, Verlag, 1974: 673-685.
24. Kakkar P et al. A modified spectrophotometric assay of superoxide dismutase. Ind J Biochem Biophys 1984; 21: 130-132.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248-254.
26. Chiariello M et al. A biochemical method for the quantitation of myocardial scarring after experimental coronary artery occlusion. J Mol Cell Cardiol 1986; 18: 283-290.
27. Murtuza B et al. Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. PNAS 2004; 101: 4216-4221.
28. Zhang GX et al. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 2005; 65: 230-238.
29. Sawyer DB et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-388.
30. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007; 116: 1413-1423.
31. Suzuki J et al. Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. J Cardiovasc Pharmacol 1999; 34: 635-644.
32. Rathore N et al. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol Res 1998; 38: 297-303.
33. Wattanapitayakul SK, Bauer JA. Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. Pharmacol Ther 2001; 89: 187-206.
34. Escudero EM et al. Serum carboxyl-terminal propeptide of procollagen type I in exercise-induced left ventricular hypertrophy. Clin Cardiol 2004; 27: 471-474.
35. Jalil JE et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989; 64: 1041-1050.
36. Brower GL et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006; 30: 604-610.
37. Teerlink JR et al. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994; 75: 105-113.
38. Benjamin IJ et al. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989; 65: 657-670.
39. Zhao W et al. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 2008; 317: 43-50.
40. Leenen FH et al. Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol 2001; 281: H2410-H2416.
41. Oliveira EM, Krieger JE. Chronic beta-adrenoceptor stimulation and cardiac hypertrophy with no induction of circulating renin. Eur J Pharmacol 2005; 520: 135-141.
42. Gagnon C et al. Diverse effects of ACE inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97: 373-381.
43. Pechanova O. Contribution of captopril thiol group to the prevention of spontaneous hypertension. Physiol Res 2007; 56(Suppl. 2): S41-S48.
44. Gallego M et al. Spironolactone and captopril attenuates isoproterenol-induced cardiac remodeling in rats. Pharmacol Res 2001; 44: 311-315.
45. Farina NK et al. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens 2000; 18: 749-755.
46. Khattab MM et al. Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxidedeficient hypertensive rat. Kidney Blood Press Res 2005; 28: 243-250.
47. Clozel JP et al. Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. Hypertension 1991; 18(Suppl. 4): II8-II14.
48. Milanez MC et al. Effects of captopril on interstitial collagen in the myocardium after infarction in rats. J Card Fail 1997; 3: 189-197.
49. Reddy DS et al. Role of cardiac renin-angiotensin system in the development of pressure-overload left ventricular hypertrophy in rats with abdominal aortic constriction. Mol Cell Biochem 1996; 155: 1-11.